Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 3:48 pm Sale | 2023-12-31 | 13G | Trevi Therapeutics, Inc. TRVI | Fairmount Funds Management LLC | 0 0.000% | -6,018,465 (Position Closed) | Filing History |
| 2024-02-14 3:48 pm Purchase | 2023-12-31 | 13G | Astria Therapeutics, Inc. ATXS | Fairmount Funds Management LLC | 3,633,965 9.900% | 1,732,568 (+91.12%) | Filing History |
| 2024-02-14 3:47 pm Purchase | 2023-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | Fairmount Funds Management LLC | 6,632,015 9.900% | 1,362,728 (+25.86%) | Filing History |
| 2024-02-14 3:46 pm Purchase | 2023-12-31 | 13G | Axsome Therapeutics, Inc. AXSM | Fairmount Funds Management LLC | 2,360,077 4.900% | 15,097 (+0.64%) | Filing History |
| 2024-02-14 3:46 pm Purchase | 2023-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | Fairmount Funds Management LLC | 2,883,221 8.100% | 740,169 (+34.54%) | Filing History |
| 2024-02-14 3:45 pm Sale | 2023-12-31 | 13G | Annexon, Inc. ANNX | Fairmount Funds Management LLC | 322,893 0.400% | -3,358,563 (-91.23%) | Filing History |
| 2024-02-14 3:45 pm Purchase | 2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | Fairmount Funds Management LLC | 2,131,369 5.200% | 6,744 (+0.32%) | Filing History |
| 2024-01-31 4:30 pm Purchase | 2024-01-29 | 13D | Apogee Therapeutics, Inc. APGE | Fairmount Funds Management LLC | 5,403,053 9.990% | 1,496,851 (+38.32%) | Filing History |
| 2024-01-24 5:26 pm Purchase | 2024-01-22 | 13D | Dianthus Therapeutics, Inc. DNTH | Fairmount Funds Management LLC | 2,960,747 9.900% | 1,086,914 (+58.00%) | Filing History |
| 2024-01-24 5:12 pm Purchase | 2024-01-22 | 13D | Viridian Therapeutics, Inc. VRDN | Fairmount Funds Management LLC | 13,956,685 19.430% | 1,192,292 (+9.34%) | Filing History |
| 2023-12-29 5:00 pm Sale | 2023-12-29 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 836,459 2.320% | -2,977,442 (-78.07%) | Filing History |
| 2023-12-11 5:21 pm Unchanged | 2023-12-07 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 3,813,901 10.590% | 0 (Unchanged) | Filing History |
| 2023-11-29 5:08 pm Purchase | 2023-11-24 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 3,813,901 12.700% | 3,813,901 (New Position) | Filing History |
| 2023-11-03 4:30 pm Purchase | 2023-10-30 | 13D | Viridian Therapeutics, Inc. VRDN | Fairmount Funds Management LLC | 12,764,393 19.990% | 3,571,579 (+38.85%) | Filing History |
| 2023-10-10 4:30 pm Purchase | 2023-09-28 | 13G | Soleno Therapeutics, Inc. SLNO | Fairmount Funds Management LLC | 950,000 6.200% | 950,000 (New Position) | Filing History |
| 2023-09-21 4:32 pm Purchase | 2023-09-11 | 13D | Dianthus Therapeutics, Inc. DNTH | Fairmount Funds Management LLC | 1,873,833 12.700% | 1,873,833 (New Position) | Filing History |
| 2023-08-10 4:15 pm Purchase | 2023-08-02 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | Fairmount Funds Management LLC | 2,143,052 6.100% | 2,143,052 (New Position) | Filing History |
| 2023-07-21 4:31 pm Purchase | 2023-07-13 | 13D | Apogee Therapeutics, Inc. APGE | Fairmount Funds Management LLC | 3,906,202 9.990% | 3,906,202 (New Position) | Filing History |
| 2023-07-07 4:00 pm Purchase | 2023-06-28 | 13G | Axsome Therapeutics, Inc. AXSM | Fairmount Funds Management LLC | 2,344,980 5.000% | 333,333 (+16.57%) | Filing History |
| 2023-06-30 5:24 pm Purchase | 2023-06-22 | 13D | Aeglea BioTherapeutics, Inc. AGLE | Fairmount Funds Management LLC | 783,600 19.990% | 783,600 (New Position) | Filing History |